If you’re following the use of gene editing for sequence replacement via aka homology directed repair (HDR), you probably noticed the two papers in Nature Biotech simultaneously reporting the use of a ligase IV inhibitor called SCR7 to improve the process. The idea was to suppress non-homologous end joining (NHEJ), thereby tipping the balance towards HDR. This sounds great in theory and the results looked pretty good in the two papers. 

But now there’s some confounding news out from Tocris Bioscience, first reported by Derek Lowe (to the best of my knowledge). Tocris is pretty careful and did their homework when making their own SCR7 for sale. And it turns out that the published structure of SCR7 is somewhat at odds with the actual compound. SCR7 instead turns into a pyrazine. 

scr7 SCR7
scr7pyrazine pyrazine

We tried SCR7 long ago (actually a while before the NBT papers came out), but never really had any luck with it in a variety of settings. When the papers appeared we did a double-take and re-tried using the exact same sources and similar conditions, again with no luck. It’s true that we typically do HDR using single stranded donors in human cells, which is not exactly the use case described in the NBT papers. But now I’m wondering what really underlies the observed SCR7 activity. Is it NHEJ inhibition? If the compound lot originally identified as a LigIV inhibitor was also actually the pyrazine, then it’s a pretty clear cut case and one can just substitute the altered structure for the original. But if the LigIV inhibitor is not the HDR enhancer, then things quickly get confusing. We’ll certainly go back and try again with the defined pyrazine, but it’s likely that the compound in the first two papers and from the original supplier were just the pyrazine. All of this on the heels of a papers out in NAR and Nature Communications indicating that SCR7 doesn’t do much at all and one should instead use a Rad51 activator called RS-1. The plot thickens.


Jacob Corn Medium Square Portrait - Innovative Genomics Initiative (IGI)

Jacob Corn

Jacob Corn is the Scientific Director of the IGI and faculty at UC Berkeley. Follow him on twitter @jcornlab.


  1. Daniel Durocher

    Hi Jacob,

    Thanks for this. Similarly to you, we obtained SCR7 (from xcessbio) and had no luck in stimulating HR in a variety of settings (DR-GFP and gene targeting assays) but obviously we haven’t tried the pyrazine compound.

    1. Antony

      SCR7 is neither a selective nor a potent inhibitor of human DNA ligase IV.
      please check this article in DNA repair..

  2. Betty

    It seems that they get the research result by accident and can only be repeated with luck. That’s the uncertainty of science. Is it possible that the human cells they applied lead to the difference?

  3. Eric Danner

    I am curious if you all have tried the pyrazine compound and compared it to the SCR7. It is an intriguing article. Thanks!

    1. Jacob Corn Post author

      We didn’t try the pyrazine from Tocris, but when the two NBT papers came out we went back and bought a new batch of compound from their exact source. We didn’t see much of an effect for the loci and cells we tested.

      1. Antony

        SCR7 is neither a selective nor a potent inhibitor of human DNA ligase IV.
        please check this article in DNA repair..

  4. Antony

    SCR7 is neither a selective nor a potent inhibitor of human DNA ligase IV.
    Check this article in DNA repair..



Your email address will not be published. Required fields are marked *


Latest Blog Posts

October 16, 2016 0 Comments

Sequence replacement to cure sickle cell disease

My lab recently published a paper, together with outstanding co-corresponding authors David Martin (CHORI) and Dana Carroll (University of Utah), in which...

September 12, 2016 1 Comment

Improved knockout with Cas9

Cas9 is usually pretty good at gene knockout. Except when it isn’t. Most people who have gotten their feet wet with gene editing have had an experience like...

August 29, 2016 0 Comments

Safety for CRISPR

This post is all about establishing safety for CRISPR gene editing cures for human disease. Note that I did not say this post is about gene editing off-targets....

Blog Archive

@jcornlab Tweets

@igisci Tweets